ReviewJournal of medicine and life2025
Risk factors and predisposing conditions for amniotic fluid embolism: a comprehensive review.
Review in Journal of medicine and life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Amniotic fluid embolism complicated by pulmonary embolism leading to multiple organ dysfunction: case report.Frontiers in medicine · 2026Article
- Successful management of amniotic fluid embolism with cardiac arrest and liver rupture: a case report.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amniotic fluid embolism (AFE) is a rare, yet life-threatening obstetric emergency characterised by sudden collapse of the mother due to circulatory and respiratory failure, often accompanied by coagulopathy. It accounts for a significant proportion of peripartum cardiac arrests and maternal deaths, with an incidence of 2-8 per 100,000 deliveries. The specific pathophysiology behind AFE remains unclear. However, one hypothesis states that amniotic fluid or fetal debris enters the maternal circulation, triggering a severe inflammatory and immunologic response. Diagnosis of AFE is primarily clinical as it relies on exclusion due to the unavailability of any definitive diagnostic test. Risk factors include caesarean delivery, multiple pregnancies, advanced maternal age, and pre-existing health conditions or comorbidities. Effective management centres on early recognition, aggressive, urgent supportive measures, and resuscitation. Advanced therapeutic options, such as veno-arterial extracorporeal membrane oxygenation (VA-ECMO), have shown potential in severe cases. Despite medical advancements in supportive care, which have led to reduced mortality rates, AFE remains highly unpredictable, carrying a significant risk of maternal and fetal mortality and morbidity. Survivors are often faced with long-term complications such as neurological deficits and cardiac problems. This comprehensive review aims to improve clinicians' awareness of AFE, summarize its risk factors, and provide an overview of the current strategies for early recognition and management, emphasizing recent advancements and the need for continued research in this critical area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.